Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib
JAMA Dermatology · 2023
DOI: 10.1001/jamadermatol.2022.6250 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2023. Verfasst von Birao Fan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Epidermolysis Bullosa Acquisita, Epidermolysis Bullosa. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
This case report describes a patient with recurrent epidermolysis bullosa acquisita who was treated with tofacitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Peking University First Hospital, Beijing, China.
- National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
- Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.
Zitieren
APA
Fan, B., & Wang, M. (2023). Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2022.6250
Vancouver
Fan B, Wang M. Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib. JAMA Dermatology. 2023. doi:10.1001/jamadermatol.2022.6250
BibTeX
@article{Fan2023,
author = {Fan, Birao and Wang, Mingyue},
title = {Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib},
journal = {JAMA Dermatology},
year = {2023},
doi = {10.1001/jamadermatol.2022.6250}
}
EUVIMED